Brief: Goldman Sachs Group's Long Position In JW (Cayman) Therapeutics Increases To 5.28% - HKEX Filing
Nov 10 (Reuters) - Hong Kong stock exchange filing:
* THE GOLDMAN SACHS GROUP INC'S LONG POSITION IN JW (CAYMAN)
THERAPEUTICS 2126.HK INCREASES TO 5.28% FROM 4.92% ON NOV 4 -
HKEX FILING
Source text in English: https://bit.ly/38pGvfb
Further company coverage: 2126.HK
(Reporting by Hong Kong newsroom)
((twinnie.siu@tr.com; 852-3462 7715;))
Recent news on JW (Cayman) Therapeutics Co
See all newsChina pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License